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Background: Folate and vitamin B12 are essential nutrients, whose deficiencies are considerable public health
problems worldwide, affecting all age groups. Low levels of these vitamins have been associated with high
concentrations of homocysteine (Hcy) and can lead to health complications. Several genetic polymorphisms affect
the metabolism of these vitamins. The aims of this study were to assess folate, vitamin B12 and homocysteine
status in distinct Brazilian individuals after the initiation of folic acid fortification by Brazilian authorities and to
investigate the effects of RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms on folate, vitamin B12 and
Hcy levels in these populations.
Methods: A total of 719 individuals including the elderly, children, as well as pregnant and lactating women were
recruited from our health care center. Folate, vitamin B12 and Hcy levels were measured by conventional methods.
Genotype analyses of RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms were performed by PCR-RFLP.
Results: The overall prevalence of folate and vitamin B12 deficiencies were 0.3% and 4.9%, respectively. Folate
deficiency was observed only in the elderly (0.4%) and pregnant women (0.3%), whereas vitamin B12 deficiency
was observed mainly in pregnant women (7.9%) and the elderly (4.2%). Plasma Hcy concentrations were
significantly higher in the elderly (33.6%). Pregnant women carrying the MTHFR 677TT genotype showed lower
serum folate levels (p = 0.042) and higher Hcy levels (p = 0.003). RFC1 A80G and GCPII C1561T polymorphisms did
not affect folate and Hcy levels in the study group. After a multivariate analysis, Hcy levels were predicted by
variables such as folate, vitamin B12, gender, age and RFC1 A80G polymorphism, according to the groups studied.
Conclusion: Our results suggest that folate deficiency is practically nonexistent in the post-folic acid fortification era
in the subgroups evaluated. However, screening for vitamin B12 deficiency may be particularly relevant in our
population, especially in the elderly.
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Folate and vitamin B12 are essential nutrients, and their
deficiencies represent public health problems worldwide,
affecting all age groups and leading to complications
such as anemia, birth defects and neurological disorders
[1,2]. Low concentrations of folate and vitamin B12 are
also associated with high homocysteine (Hcy) levels,
considered a risk factor for cardiovascular disease, cogni-
tive decline and adverse pregnancy outcomes [2-4].
Folate deficiency can be caused by inadequate dietary
intake, medications (methotrexate and anticonvulsants),
alcoholism and conditions associated with increased cell
turnover. In addition, a few genetic polymorphisms have
been shown to influence folate levels. On the other
hand, vitamin B12 deficiency results mainly from gastro-
intestinal conditions leading to vitamin B12 malabsorp-
tion, and less frequently from intestinal parasitosis and
genetic polymorphisms [5].
Genetic polymorphisms such as reduced folate carrier
(RFC1) A80G and glutamate carboxypeptidase II (GCPII)
C1561T have also been shown to impair folate transport
and absorption, respectively, thus affecting the bioavail-
ability of the dietary folate [6,7]. The methylenetetrahydro-
folate reductase (MTHFR) C677T polymorphism is
associated with elevated Hcy levels and reduced folate and
vitamin B12 levels [8,9].
Fortification of white flour with folic acid is mandatory
in several countries and has proved to be a successful
public health intervention. Although the major purpose
of folic acid fortification is to reduce the occurrence of
neural tube defects (NTD) during pregnancy, an add-
itional benefit is a potential protection against chronic
diseases, through its association with lower Hcy levels
[10,11]. In Brazil, this strategy has been applied since
2004 by the National Health Surveillance Agency,
ANVISA [12]. Fortification was implemented to provide
an adequate intake of folate mainly for vulnerable popu-
lations, such as pregnant women, lactating women, chil-
dren and the elderly [13,14].
In this context, the aims of this study were: (1) to
assess folate and vitamin B12 status, as well as the
frequency of elevated Hcy levels among the elderly,
children, pregnant women and lactating women con-
secutively assisted at a public health care center after
folic acid fortification; and (2) to investigate the effects
of RFC1 A80G, GCPII C1561T and MTHFR C677 poly-
morphisms on folate, vitamin B12 and Hcy levels in the
same study groups.
Methods
Study population
Seven hundred and nineteen participants were enrolled
from April 2006 to May 2007, and divided into the fol-
lowing subgroups: 262 elderly individuals (≥60 year old),106 children (≤6 year old), 291 pregnant women and 60
lactating women. The study group was chosen based on
their vulnerability to vitamin deficiencies. We excluded
individuals who had hypothyroidism, renal and hepatic
disease, and those using agents that affect vitamin B me-
tabolism such as methotrexate and anticonvulsants. In
addition, individuals with acute illnesses were also ex-
cluded. Information regarding age, gender, height,
weight, medical history, smoking, use of multivitamin
supplements and gestational stage were collected.
The study groups were composed of individuals con-
secutively attended to at a public health care center in
the northern area of the city of Campinas, Brazil, during
visits to primary care physicians. Our recruitment goal
was 250 individuals from each group, but due to the ex-
clusion criteria and rate of refusal to participate this
number could not be reached. Thus, all eligible partici-
pants, who were in accordance with the study protocol
and who agreed to participate in the study, provided a
written informed consent. For children, the written in-
formed consent was obtained from mothers or guard-
ians. The study protocol was approved by the Ethics
Committee of the University of Campinas.
Blood collection
Fasting blood samples were obtained from all participants
in tubes without anticoagulant, for measurement of folate
and vitamin B12, and in tubes containing EDTA to meas-
ure Hcy levels and for the genetic analyses (RFC1 A80G,
GCPII C1561T and MTHFR C677T). Serum and plasma
samples were processed within 3 hours of collection and
stored below −80°C until analyses.
Laboratory assays
Serum levels of folate and vitamin B12 were determined
using chemiluminescence immunoassays (Elecsys/Roche
Diagnostics, Mannheim, Germany). Hcy in plasma was
assessed by high-performance liquid chromatography
(HPLC) with fluorescence detection [15]. Genomic DNA
was isolated from whole blood by standard methods.
The analyses of RFC1 A80G, GCPII C1561T and
MTHFR C677T polymorphisms were accomplished by
PCR-RFLP. The amplified fragments were digested by
restriction enzymes (HinfI, HhaI and AccI, respectively),
as previously described [6,16,17].
We separated folate, vitamin B12 and Hcy levels into cat-
egories, based on the reference values used in our service.
For folate levels, categories were: <4 ng/mL, ≥4 ng/mL; for
vitamin B12: <200 pg/mL, 200 – 300 pg/mL, >300 pg/mL;
and for Hcy levels, these categories were: <15 μmol/L,
≥15 μmol/L. Individuals with levels of folate below 4 ng/
mL and vitamin B12 below 200 pg/mL were categorized as
having deficiency. Vitamin B12 levels between 200 –
300 pg/mL were considered as marginal status [5,14].
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is noteworthy that the reference values used to describe
folate and vitamin B12 deficiencies are similar to those
cited by WHO [19].Statistical analysis
Data are expressed as median, percentiles 25 and 75, ab-
solute number and percentages. Medians were compared
using the Mann–Whitney test for 2-group comparisons
and the Kruskal-Wallis test for 3-group comparisons.
The Hardy-Weinberg equilibrium test was performed
for all genotypes using the chi-square test. Multiple
linear regression analysis with stepwise criteria was per-
formed for Hcy as the dependent variable and folate,
vitamin B12, polymorphisms, age, gender, body mass
index, hypertension, diabetes and smoking as the inde-
pendent variables. This analysis was adjusted for gesta-
tional stage in pregnant women. Statistical tests were
performed using SPSS software for Windows version
17.0 (SPSS Inc, Chicago, IL, USA) and SAS System for
Windows version 9.2 (SAS Institute Inc, Cary, NC, USA)
with the level of significance set at p < 0.05.Results
During the enrollment period, all individuals who assisted
at a public health care center were invited to participate in
the study. A total of 719 individuals were included in our
study. Among them, 40.5% were pregnant women, 36.5%
were elderly, 14.7% were children and 8.3% were lactating
women. The demographic characteristics of the studied
population are summarized in Table 1.Table 1 Demographic characteristics of the study population
Elderly Childre
(N = 262) (N = 10
Age (y) 67 (60 – 91) 3 (0.5 -
Gender (male) 114 54
BMI (mean ± SD) 26.7 (23.9, 29.9) 15.9 (14
Supplementation1 [n (%)] 43 (16.4) 22 (16.6
Smoking [n (%)] 20 (7.6) -
Hypertension2 [n (%)] 158 (60.3) -
Diabetes [n (%)] 65 (24.8) 3 (2.8)
Dyslipidemia [n (%)] 65 (24.8) -
Gestational stage3 n (%)]
First trimester - -
Second trimester - -
Third trimester - -
Age is expressed as median and range in parentheses. Body Mass Index (BMI) is exp
expressed as number of individuals.
1Users of multivitamins or folic acid supplements.
2Hypertension definition: blood pressure exceeding 140 over 90 mmHg.
3Gestational stage was not available for 28 pregnant women.Folate, vitamin B12 and homocysteine levels
Among the distinct study groups, children had higher
vitamin B12 levels, the elderly had higher Hcy levels and
lactating women had lower folate levels (Table 2).
The overall frequency of folate and vitamin B12 defi-
ciencies were estimated to be 0.3% and 4.9% respectively
(Table 3). Interestingly, we observed no folate or vitamin
B12 deficiencies in the children included in our study,
and only 1% presented marginal status of vitamin B12.
Folate deficiency could be identified in 0.4% of elderly
and 0.3% of pregnant women. None of the lactating
women showed folate deficiency. The pregnant women
group was the one which presented a higher frequency
of vitamin B12 deficiency (7.9%), followed by the elderly
(4.2%) and lactating women (1.9%). Marginal status of
vitamin B12 was observed in 14.5% of the elderly, 33.7%
of pregnant women and 7.4% of lactating women. The
frequency of elevated Hcy levels was observed mainly in
the elderly (33.6%). Among pregnant and lactating
women, the frequencies of elevated Hcy levels were 0.7
and 5.0%, respectively.
Effects of polymorphisms RFC1 A80G, GCPII C1561T and
MTHFR C677T in the studied population
In order to assess the effects of polymorphisms on fol-
ate, vitamin B12 and Hcy levels we compared the me-
dian of these parameters in individuals with different
genotypes (Table 4). Folate, vitamin B12 and Hcy con-
centrations were not affected by the RFC1 A80G, GCPII
C1561T and MTHFR C677T polymorphisms in the eld-
erly, children and lactating women. Pregnant women
carrying the MTHFR 677TT genotype showed lowern Pregnant women Lactating women
6) (N = 291) (N = 60)
6) 26 (14–43) 26.5 (14–40)
- -
.8, 17.9) 26.4 (23.4, 30.7) 23.4 (21.5, 26.4)
) 138 (47.4) 10 (16.6)
27 (9.3) 8 (13.3)
42 (14.4) 5 (8.3)
12 (4.1) 1 (1.6)
2 (0.7) -
73 (27.8) -
125 (47.5) -
65 (24.7) -
ressed as median and percentiles (25 and 75) in parentheses. Gender is
Table 2 Folate, vitamin B12, and Hcy levels in different
study groups
Groups Folate
(ng/mL)
Vitamin B12
(pg/mL)
Hcy1
(μmol/L)
Elderly 11.2(8.7, 13.6) 443(333, 620.2) 13.5(11.1, 17.1)
N = 262 N = 262 N = 262
Children 12.4(9.4, 14.6) 853.0(611, 1188) 6.2(5.2, 7.3)
N = 103 N = 103 N = 105
Pregnant women 10.7(8.3, 14.1) 325.0(257, 424) 6.4(5.3, 7.5)
N = 291 N = 291 N = 291
Lactating women 9.8(7.6, 12.2) 523.0(415.7, 641.5) 9.2(7.6, 10.8)
N = 54 N = 54 N = 60
P2 0.003 p < 0.001 p < 0.001
All values are expressed as median and percentiles (25 and 75).
1Hcy, homocysteine.
2Kruskal-Wallis test.
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(p = 0.003).
Homozygosity for the GCPII C1561T polymorphism
was not found in our population.
Genotype distributions of RFC1 A80G, GCPII C1561T
and MTHFR C677T polymorphisms were in Hardy-
Weinberg equilibrium. Table 5 summarizes the frequen-
cies of genotypes for each polymorphism studied.
Impact of clinical and laboratory parameters on Hcy
levels
We next evaluated the impact of clinical and laboratorial
parameters on Hcy levels (Table 6). Using a multiple lin-
ear regression analysis with stepwise criteria, the vari-
ables independently associated with Hcy levels were:
folate, vitamin B12, gender, age and RFC1 A80G poly-
morphism (genotype AA) in the elderly; vitamin B12 in
children; and folate in pregnant women. None of the
variables evaluated showed any impact on Hcy levels in
lactating women.Table 3 Folate, vitamin B12 and Hcy status according to cut-o
Cut-off values All Elderly
N, % N, %
Folate
<4 ng/mL 2, 0.3 1, 0.4
≥4 ng/mL 708, 99.7 261, 99.6
Vitamin B12
<200 pg/mL 35, 4.9 11, 4.2
200 - 300 pg/mL 141, 19.9 38, 14.5
>300 pg/mL 534, 75.2 213, 81.3
Homocysteine
<15 μmol/L 625, 87.0 174, 66.4
≥15 μmol/L 93, 13.0 88, 33.6Discussion
The present study suggests that fortification of flour
with folic acid has been effective, as folate deficiency was
practically nonexistent (0.3%), whereas vitamin B12 defi-
ciency was present in 4.9% of the studied group. A previ-
ous study performed with Brazilian adults reported that
folate deficiency was not detected and vitamin B12 defi-
ciency was over 6% [20]. Similarly, folate deficiency is
practically nonexistent and vitamin B12 deficiency is ap-
proximately 5% in the Canadian population [11]. In devel-
oped countries, folate deficiency is uncommon; however
this deficiency can still be observed in some developing
countries [21]. In addition, the prevalence of folate and
vitamin B12 deficiencies vary between different studies
due to differences in the assays employed [13].
We believe that our results represent the profile of these
vitamins in the investigated group, as the measurements
were performed in 719 individuals of various ages under
several clinical conditions using laboratory methods con-
sidered suitable for analysis. Furthermore, the subgroup-
specific evaluation is also important, enabling the identifi-
cation of individuals at an increased risk of developing
vitamin deficiencies. These individuals should be consid-
ered for specific prophylactic measures, as a problem in
clinical practice is that sometimes the deficiencies are
identified only when complications, such as anemia, NTD,
and neurological disorders, have already occurred. Thus,
prevention of folate and vitamin B12 deficiencies becomes
a major challenge for health worldwide.
As described previously, folate deficiency may occur at
any age, mostly in individuals ingesting a poor diet or
suffering from intestinal malabsorption [22]. Moreover,
vitamin B12 levels frequently decrease with age due to
malabsorption of vitamins from food, which is more
common in the elderly [11]. Approximately 10% of the
elderly are estimated to present reduced levels of vita-
min B12, with this prevalence increasing approximately
5% at the age of 65 years and to 20% at the age offf values
Children Pregnant women Lactating women
N, % N, % N, %
- 1, 0.3 -
103, 100 290, 99.7 54, 100
- 23, 7.9 1, 1.9
1, 1.0 98, 33.7 4, 7.4
102, 99.0 170, 58.4 49, 90.7
105, 100 289, 99.3 57, 95.0
- 2, 0.7 3, 5.0
Table 4 Folate, vitamin B12 and Hcy levels according to different polymorphisms in the study groups
GROUPS RFC1 A80G3 P1 GCPII C1651T4 P2 MTHFR C677T5 P1
AA AG GG CC CT CC CT TT
Folate (ng/mL)
Elderly 11.2 (8.4,13.2) 11.2 (8.8, 13.9) 11 (8.6, 13.2) 0.840 11 (8.5, 13.7) 12.2 (11.1, 13) 0.252 11.2 (8.6, 13.3) 11 (8.8, 14.2) 10.2 (7.3, 12.4) 0.158
N = 49 N = 125 N = 86 N = 241 N = 14 N = 103 N = 118 N = 36
Children 12.5 (8.2,16.1) 12.5 (9.4, 15.1) 12.5 (10.2, 14.1) 0.863 12 (9.4, 15.1) 11.5 (8.2, 18.3) 0.932 12.0 (9.3, 14.4) 12.5 (9.2, 14.9) 13.8 (9.6, 15.6) 0.441
N = 20 N = 60 N = 20 N = 79 N = 6 N = 51 N = 32 N = 11
Pregnant
women
9.8 (8.0,13.6) 11 (8.4, 15) 10.9 (8.5, 14.2) 0.346 10.8 (8.2, 14.3) 11.5 (8.5, 13.3) 0.927 11.2 (9, 15) 10.8 (7.7, 14) 8.8 (7.3, 11.6) 0.042
N = 74 N = 129 N = 83 N = 250 N = 21 N = 139 N = 113 N = 26
Lactating
women
10.6 (9.4,12.7) 9.5 (7, 12.1) 9.5 (7.3, 11.7) 0.300 9.8 (7.7, 12) 12.6 (7.5, 14.3) 0.429 10 (9.1, 12.5) 9.3 (7.1, 13.1) 9.7 (6.8, 10.8) 0.723
N = 12 N = 28 N = 14 N = 49 N = 3 N = 27 N = 21 N = 4
Vitamin B12 (pg/mL)
Elderly 418 (310, 687.5) 446 (341, 623) 442 (337.5, 584.7) 0.650 444 (333,
616.5)
373.5 (288.2, 647.7) 0.317 463 (345, 594) 431 (330.5, 627.5) 391.5 (276.2,
577.5)
0.443
N = 49 N = 125 N = 86 N = 241 N = 14 N = 103 N = 118 N = 36
Children 827 (638.5,
1047.5)
874 (650.2,
1200)
770.5 (513,
1207.2)
0.840 901 (611,
1204)
772.5 (518.7,
1000.5)
0.359 790 (572,
1109)
918.5 (660.2,
1206)
756 (553, 1049) 0.333
N = 20 N = 60 N = 20 N = 79 N = 6 N = 51 N = 32 N = 11
Pregnant
women
341.5 (267.7, 462) 324 (253, 419) 319 (240, 412) 0.218 322 (253.7,
424)
324 (263.5, 399.5) 0.738 321 (249, 420) 334 (257.5, 425) 308.5 (236.2,
441.7)
0.703
N = 74 N = 129 N = 83 N = 250 N = 21 N = 139 N = 113 N = 26
Lactating
women
563 (470, 648) 467 (400.2,
540.7)
624 (408.7, 682) 0.114 488 (414,
622.5)
627 (576, 699) 0.094 488 (437, 627) 485 (377, 551.5) 617 (520, 712) 0.137
N = 12 N = 28 N = 14 N = 49 N = 3 N = 27 N = 21 N = 4
Homocysteine (μmol/
L)
Elderly 14.1 (11.7, 17.9) 12.9 (10.7, 16.4) 13.8 (11.4, 17.2) 0.170 13.5 (11.2,
17.1)
13.3 (10.7, 18.4) 0.896 13.2 (10.9,
15.7)
13.3 (10.8, 17.2) 14.8 (12.1, 18.4) 0.087
N = 49 N = 125 N = 86 N = 241 N = 14 N = 103 N = 118 N = 36
Children 6.0 (5.3, 6.7) 6.3 (5.1, 7.4) 6.7 (5.2, 7.4) 0.582 6.2 (5.2, 7.1) 5.9 (5.2, 8.4) 0.876 6.2 (5.4, 7.2) 5.8 (4.9, 7.5) 6.8 (6.5, 8) 0.099
N = 20 N = 60 N = 20 N = 78 N = 6 N = 51 N = 32 N = 11
Pregnant
women
5.9 (5.1, 7.6) 6.4 (5.4, 7.6) 6.3 (5.5, 7.5) 0.151 6.4 (5.4, 7.5) 6.2 (5.1, 7.8) 0.710 6.2 (5.4, 7.4) 6.3 (5.2, 7.3) 7.8 (6.3, 9.2) 0.003
N = 74 N = 129 N = 83 N = 250 N = 21 N = 139 N = 113 N = 26
Lactating
women
9.4 (8.2, 10.4) 9.7 (7.4, 11.5) 8.7 (7.8, 10.9) 0.929 9.4 (7.5, 10.8) 12.6 (8.9, 12.6) 0.193 9.4 (7.6, 10.7) 9.9 (8, 11.9) 7.8 (6.8, 11.4) 0.529
N = 12 N = 28 N = 14 N = 49 N = 3 N = 27 N = 21 N = 4
Values are expressed as median and percentiles (25 and 75).
1Kruskal-Wallis test.
2Mann-Whitney test.
3AA, wild type; AG, heterozygous; and GG homozygous mutant for the RFC1 A80G polymorphism.
4CC, wild type; and CT, heterozygous for the GCPII C1561T polymorphism.
5CC, wild type; CT, heterozygous; and TT, homozygous mutant for the MTHFR C677T polymorphism.
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Table 5 Overall genotype frequencies of RFC1 A80G,
GCPII C1561T and MTHFR C677T polymorphisms
Polymorphisms Genotypes Study groups
N %
RFC1 A80G1
AA 158 22.3
AG 343 48.4
GG 207 29.3
GPCII C1561T2
CC 619 93.4
CT 44 6.6
MTHFR C677T3
CC 326 47.3
CT 286 41.5
TT 77 11.2
1AA, wild type; GA, heterozygous; and GG homozygous mutant for the RFC1
A80G polymorphism.
2CC, wild type; and CT, heterozygous for the GCPII C1561T polymorphism.
3CC, wild type; CT, heterozygous; and TT, homozygous mutant for the MTHFR
C677T polymorphism.
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of the elderly with folate and vitamin B12 deficiencies re-
spectively, whereas 14.5% showed marginal levels of vita-
min B12. Coussirat et al. evaluated 545 Brazilian elderly
individuals, and detected 0.5% with folate deficiency, 5.5%
with vitamin B12 deficiency, while 23.3% had marginal
levels of vitamin B12. Xavier et al. showed that 7.2% of
the elderly had a vitamin B12 deficiency [20,23].
Our results show a situation that can often go un-
noticed in the elderly, which is a vitamin B12 deficiency.Table 6 Predictors of Hcy levels in the elderly, children
and pregnant women
Groups Independent
variables
β R2 P
Elderly
Folate −4.594 0.0441 p < 0.001
Vitamin B12 −0.044 0.0324 p < 0.001
Gender (male) 52.785 0.1622 p < 0.001
Age 3.219 0.0716 p < 0.001
RFC1 (AG x AA) −26.995 0.0192 0.011
(GG x AA) −11.736
Children
Vitamin B12 −0.023 0.0782 0.011
Pregnant
women
Folate −4.556 0.0750 p < 0.001
Multiple linear regression analysis with stepwise criteria. Independent
variables: age, gender (male versus female), smoking, hypertension, diabetes,
dyslipidemia, BMI, polymorphisms (RFC1 A80G, GCPII C1561T e MTHFR C677T),
folate and vitamin B12. In pregnant women, the analysis was adjusted for
gestational stage.Atrophy of the gastric mucosa, the presence of auto-
antibodies against intrinsic factors (often undiagnosed),
or the presence of H. pylori may play a role as an etio-
logical factor of vitamin B12 deficiency in this age group,
because it results in malabsorption of vitamin B12.
Although almost all of these individuals in our study
showed no anemia (data not shown), it should be empha-
sized that symptoms such as depression, dementia and
impaired cognitive function, which have been associated
with vitamin B12 deficiency, may be misinterpreted as
aging-related co-morbidities rather than vitamin B12
dependent co-morbidities [24-26]. In this sense, our find-
ings have great relevance in clinical practice, suggesting
that the measurement of this vitamin should be part of
routine diagnosis in patients over 60 years, even in the ab-
sence of hematological symptoms. The high frequency of
elderly individuals with marginal levels of vitamin B12 is
another important fact, although the clinical significance
of these levels on their health are not clear [27].
Children aged from 0.5 – 6 years, included in our
study, did not exhibit folate and vitamin B12 deficien-
cies. Several studies conducted in developing countries,
such as Colombia, have described a very low prevalence
of deficiency of these vitamins [28]. In Brazil, a study
that included 1111 Amazonian children reported a folate
and vitamin B12 deficiency of 2.5 and 3.7%, respectively
[29]. Another study of 164 Brazilian children showed
that deficiency of folate and vitamin B12 were present in
2.2 and 11.7%, respectively. It is important to note that
this study included children under 2 years of age, who
continued to receive cow’s milk and porridge or did not
consume vegetables, fruits, and animal products until
over the age of one; a fact that might have contributed
to the high prevalence of vitamin B12 deficiency [30].
Shakur et al. showed that since food fortification with folic
acid, folate deficiency has been reduced to practically 0%
in children aged 1 – 14 years in Canada [31]. These results
suggest that there is apparently no additional advantage of
supplementation with folic acid in countries where food
products are folic acid-fortified [14].
Our results suggest that fortification was adequate to
prevent folate deficiency in these children, and that diet
was capable of meeting vitamin B12 requirements. Vita-
min B12 deficiency in children is exceptional as daily re-
quirements are very small, and children normally
consume food that contains this nutrient.
During pregnancy, folate and vitamin B12 are essential
for normal fetal development. Furthermore, pregnant
women have an increased physiological need for these
nutrients, and their inadequate intake increases the risk
of developmental abnormalities, including NTD [32,33].
The results of the present study showed that the median
of folate (10.7 ng/mL) and vitamin B12 (325.0 pg/mL) in
pregnant women were higher than those reported by
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respectively) before folic acid fortification in Brazil [34].
We highlight that folate deficiency during pregnancy
was virtually nonexistent in our study. According to
some studies, the mandatory fortification of flour with
folic acid resulted not only in an improvement in input
and levels of folate in the blood, but also in a reduction
in the occurrence of NTD [35-37]. Despite the lack of
data on the outcome of these pregnancies, our results
corroborate the effectiveness of this program, since nor-
mal folate levels were present in all pregnant women,
irrespective of folate supplementations. However, we
cannot exclude that supplementation may have contrib-
uted to achieving adequate folate levels in some of these
pregnant women.
Vitamin B12 deficiency (7.9%) or marginal levels (33.7%)
were frequent in the group of pregnant women. A high
prevalence of this deficiency in this group has also been
described in other populations [38]. Ray et al. suggested
that 1 in 20 Canadian women may be vitamin B12 defi-
cient during the critical period of closing the embryonic
neural tube [39]. Increased risk of NTD has also been as-
sociated with vitamin B12 deficiency, especially after the
fortification of flour with folic acid [40,41].
In the current study, practically all pregnant women
with vitamin B12 deficiency were in their second and
third trimester of pregnancy. It is known that vitamin
B12 decreases through gestation due to an increase in
fetal requirements [34,42,43], and therefore, the defi-
ciency in this group should be interpreted with caution.
In addition, we cannot rule out the effect of hemodilu-
tion upon the levels of vitamin B12 in pregnant women.
Moreover, the cut-off used to identify the vitamin B12
deficiency in the general population may not apply dur-
ing pregnancy.
In lactating women, a higher folate intake is also re-
quired. Folate concentration in human milk is strongly
regulated and not affected by maternal folate status, ex-
cept in clinically folate-deficient mothers [14]. Maternal
vitamin B12 levels have also been correlated with milk
vitamin B12, and infant urinary methylmalonic acid
levels, inversely related to milk vitamin B12 levels. How-
ever, in breast-fed infants the deficiency may become
clear due to the low milk concentration of vitamin B12
[44,45]. In this study, we did not observe folate defi-
ciency in lactating women; however 1.9% showed vita-
min B12 deficiency.
Although the main purpose of fortifying flour with
folic acid is the reduction of NTD, the potential benefit
of reducing the risk of cardiovascular disease by redu-
cing the levels of Hcy is also relevant [10]. Hyperhomo-
cysteinemia has been considered a risk factor for
vascular diseases and its increase is related to folate and
vitamin B12 deficiencies, and genetic polymorphisms.Some population-based studies suggest that a decline in
mortality related to strokes coincided with the introduc-
tion of folic acid fortification in the United States and
Canada [46]. However, some meta-analysis studies that
evaluated the risk of cardiovascular disease or death in pa-
tients with or without previous disease, failed to show any
beneficial effect of this strategy. Apparently, for some sub-
groups of patients, such as those with kidney disease, sup-
plementation may have a beneficial effect [47,48].
Our results showed a higher frequency of hyperhomo-
cysteinemia, mainly in the elderly. Hyperhomocysteine-
mia may be a consequence of ageing, oxidative stress,
hypertension, diabetes and dyslipidemia. These factors
were common in this group and could justify the high
frequency of this condition. Moreover, our results cor-
roborate with studies that consider the reduction of fol-
ate and vitamin B12 and age as factors related to
hyperhomocysteinemia [49,50].
On the other hand, hyperhomocysteinemia was nonex-
istent in all the children included, and multivariate ana-
lysis demonstrated the effect of vitamin B12 levels. A
study performed in 207 children from the region of
Campinas demonstrated that acquired factors, vitamin
B12 and folate, were the most important factor in defin-
ing the levels of plasma Hcy [51].
We have also observed that Hcy levels were normal in
most of the pregnant women (99.3%). Hcy levels are
known to be lower in pregnant women than in non-
pregnant women [52,53]. However, studies have reported
that elevated Hcy levels (>15.33 μmol/L) were observed
in mothers of infants with NTD [54,55]. Furthermore,
several studies have also associated high levels of Hcy to
a variety of adverse effects during pregnancy [56].
In lactating women, hyperhomocysteinemia was
present in 5%. Ramlau-Hansen et al. demonstrated that
breastfeeding mothers who did not take folic acid sup-
plements had a higher prevalence of elevated Hcy, com-
pared to breastfeeding mothers taking folic acid
supplements, and to a control population [57]. Despite
this relationship between folate and hyperhomocysteine-
mia in lactating women, the multivariate analysis showed
no factor that might interfere with Hcy levels, and this
fact can be attributed to the number of participants
included.
Among the polymorphisms investigated, only MTHFR
C677T was significantly associated with folate and Hcy
levels in pregnant women. Folate status is well-known to
play a crucial role in the development of hyperhomocys-
teinemia in individuals with this polymorphism [58,59].
Furthermore, Hcy levels tend to be independent of the
genotype in populations having high T allele frequency
(≥20%) [60,61].
No interactions of the RFC1 A80G and GCPII C1561T
polymorphisms were found on folate and Hcy levels,
Barnabé et al. Nutrition Journal  (2015) 14:19 Page 8 of 10corroborating with previous studies. The effects of poly-
morphisms in folate-metabolizing genes on Hcy levels
may be masked by the interaction with other polymor-
phisms or with environmental factors that influence fol-
ate status [62].
The frequencies of MTHFR C677T and RCF1 A80G
genotypes were similar to those reported in others popu-
lations [17,62], whereas genotype frequencies of the
GCPII C1561T polymorphism were different from those
described in other studies [6,7].
Finally, we were able to demonstrate that Hcy levels
are influenced mainly by folate and vitamin B12. Plasma
Hcy may serve as an indicator of status and perhaps of
the intake of vitamins such as folate and vitamin B12
[49]. These results also corroborate with previous find-
ings where acquired factors contributed more to hyper-
homocysteinemia than genetic factors [51].
In Brazil, a few studies have evaluated vitamin defi-
ciencies after folic acid fortification, mainly in the popu-
lation investigated and, therefore, we considered this
analysis of an impressive number of more than 700 par-
ticipants as the strength of the current study. However
some limitations should be acknowledged, such as: the
fact that our population is not representative of the en-
tire country’s population which presents great diversity;
the small number of children and lactating women in-
cluded; plasma Hcy samples were not kept on ice until
separation, and the length of time between the blood
collection and plasma preparation could have a signifi-
cant impact on plasma total Hcy; the lack of data from
the pre-fortification era to compare with the post-
fortification era; and also the lack of data regarding
food-intake to correlate with folate and vitamin B12
levels. Also, we did not perform the measurements of
red blood cell folate and methylmalonic acid. We could
not exclude that the real impact of fortification was
compromised in lactating women because this group
comprised of only 60 individuals. These limitations
should be considered when analyzing our data.Conclusion
Folate deficiency is practically nonexistent in the post-folic
acid fortification era in the studied population. However,
our study suggests that screening for vitamin B12 defi-
ciency may be particularly relevant, especially in the eld-
erly, and the impact of the relatively high frequency of this
deficiency on the overall health of our population deserves
additional studies. Regarding the influence of genetic
polymorphisms, we observed no evidence that RFC1
A80G and GCPII C1561T polymorphisms-influenced
folate, vitamin B12 and Hcy. Finally, we confirmed that
folate and vitamin B12 are important determinants of
Hcy levels.Abbreviations
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